Therapeutic evaluation of [Pb]Pb-AB001 and [Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer.
1/5 보강
[BACKGROUND] Metastatic castration-resistant prostate cancer (mCRPC) frequently leads to bone and soft tissue metastases, leading to poor prognosis.
APA
Høyvik AJK, Kvassheim M, et al. (2025). Therapeutic evaluation of [Pb]Pb-AB001 and [Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer.. European journal of nuclear medicine and molecular imaging, 52(13), 4847-4859. https://doi.org/10.1007/s00259-025-07330-y
MLA
Høyvik AJK, et al.. "Therapeutic evaluation of [Pb]Pb-AB001 and [Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer.." European journal of nuclear medicine and molecular imaging, vol. 52, no. 13, 2025, pp. 4847-4859.
PMID
40397137 ↗
Abstract 한글 요약
[BACKGROUND] Metastatic castration-resistant prostate cancer (mCRPC) frequently leads to bone and soft tissue metastases, leading to poor prognosis. The beta-emitting radioligand [Lu]Lu-PSMA-617 targets the prostate-specific membrane antigen (PSMA) and may be less efficient against micrometastatic disease. The alpha-emitting radioligand [Pb]Pb-AB001 could offer enhanced treatment by delivering high energy over a short range. This study compared the efficacy of [Pb]Pb-AB001 and [Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer.
[METHODS] Binding and internalisation of radioligands were evaluated in PC-3 PIP-luc cells. A mouse model was established by intracardiac injection of these cells. Treatments with 0.24‒1.0 MBq [Pb]Pb-AB001 or 22‒66 MBq [Lu]Lu-PSMA-617 were initiated 7 d post-cell inoculation. Metastatic burden was measured using bioluminescence imaging, and PSMA-targeted uptake was determined with [F]F-PSMA-1007 µPET/µCT. Gamma-autoradiography evaluated [Pb]Pb-AB001 distribution, and bone metastases were identified by radiography.
[RESULTS] Both radioligands displayed comparable in vitro binding. In vivo studies revealed metastatic formation in clinically relevant organs. µPET/µCT demonstrated increased [F]F-PSMA-1007 uptake in metastases, matching the bioluminescence imaging results. Focal [Pb]Pb-AB001 distribution in the metastatic xenograft indicated heterogeneously distributed micrometastases in the organs. A median survival up to 47 d was achieved with [Pb]Pb-AB001, compared to 25 d for controls and 27 d for [Lu]Lu-PSMA-617. An activity-dependent reduction in bone metastases was observed for [Lu]Lu-PSMA-617, while no bone lesions were detected in [Pb]Pb-AB001-treated mice.
[CONCLUSION] [Pb]Pb-AB001 showed significant efficacy against micrometastases and advantages over [Lu]Lu-PSMA-617 in preventing or treating early bone metastases for the investigated injected activities. This implies clinical potential for treating mCRPC, including patients at risk of early metastatic disease, but further studies including dosimetry and toxicity analyses are required with regards to activity levels.
[METHODS] Binding and internalisation of radioligands were evaluated in PC-3 PIP-luc cells. A mouse model was established by intracardiac injection of these cells. Treatments with 0.24‒1.0 MBq [Pb]Pb-AB001 or 22‒66 MBq [Lu]Lu-PSMA-617 were initiated 7 d post-cell inoculation. Metastatic burden was measured using bioluminescence imaging, and PSMA-targeted uptake was determined with [F]F-PSMA-1007 µPET/µCT. Gamma-autoradiography evaluated [Pb]Pb-AB001 distribution, and bone metastases were identified by radiography.
[RESULTS] Both radioligands displayed comparable in vitro binding. In vivo studies revealed metastatic formation in clinically relevant organs. µPET/µCT demonstrated increased [F]F-PSMA-1007 uptake in metastases, matching the bioluminescence imaging results. Focal [Pb]Pb-AB001 distribution in the metastatic xenograft indicated heterogeneously distributed micrometastases in the organs. A median survival up to 47 d was achieved with [Pb]Pb-AB001, compared to 25 d for controls and 27 d for [Lu]Lu-PSMA-617. An activity-dependent reduction in bone metastases was observed for [Lu]Lu-PSMA-617, while no bone lesions were detected in [Pb]Pb-AB001-treated mice.
[CONCLUSION] [Pb]Pb-AB001 showed significant efficacy against micrometastases and advantages over [Lu]Lu-PSMA-617 in preventing or treating early bone metastases for the investigated injected activities. This implies clinical potential for treating mCRPC, including patients at risk of early metastatic disease, but further studies including dosimetry and toxicity analyses are required with regards to activity levels.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Animals
- Male
- Mice
- Heterocyclic Compounds
- 1-Ring
- Dipeptides
- Lutetium
- Humans
- Lead Radioisotopes
- Prostatic Neoplasms
- Disease Models
- Animal
- Radioisotopes
- Radiopharmaceuticals
- Cell Line
- Tumor
- Tissue Distribution
- Neoplasm Metastasis
- Prostate-Specific Antigen
- 177Lu
- 212Pb
- Disseminated prostate cancer model
- PSMA
- Targeted alpha therapy
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.